Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$129.45
Updated
Merck & Co., Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$129.45 |
52 Week High | US$133.10 |
52 Week Low | US$99.14 |
Beta | 0.40 |
1 Month Change | 1.47% |
3 Month Change | 4.40% |
1 Year Change | 19.19% |
3 Year Change | 74.84% |
5 Year Change | 54.64% |
Change since IPO | 11,406.67% |
Recent News & Updates
Recent updates
Merck Stock: Still Discounted To Graham P/E
May 29Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why
May 22Merck Q1: There's Still Room For Growth
May 06Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To
Apr 17We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt
Apr 09Merck: Better Times Ahead On Approvals And Outlook
Apr 02Merck's Future Brightens With Winrevair's Blockbuster Potential
Mar 27Merck: A High-Conviction Investment For Long-Term Growth
Feb 29Shareholder Returns
MRK | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 2.8% | 2.5% | -0.6% |
1Y | 19.2% | 17.7% | 21.7% |
Return vs Industry: MRK exceeded the US Pharmaceuticals industry which returned 17.7% over the past year.
Return vs Market: MRK underperformed the US Market which returned 21.7% over the past year.
Price Volatility
MRK volatility | |
---|---|
MRK Average Weekly Movement | 2.5% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: MRK's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
MRK fundamental statistics | |
---|---|
Market cap | US$326.00b |
Earnings (TTM) | US$2.31b |
Revenue (TTM) | US$61.40b |
142.2x
P/E Ratio5.3x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRK income statement (TTM) | |
---|---|
Revenue | US$61.40b |
Cost of Revenue | US$15.44b |
Gross Profit | US$45.96b |
Other Expenses | US$43.66b |
Earnings | US$2.31b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
Earnings per share (EPS) | 0.91 |
Gross Margin | 74.85% |
Net Profit Margin | 3.76% |
Debt/Equity Ratio | 84.7% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield325%
Payout RatioDoes MRK pay a reliable dividends?
See MRK dividend history and benchmarksMerck dividend dates | |
---|---|
Ex Dividend Date | Jun 17 2024 |
Dividend Pay Date | Jul 08 2024 |
Days until Ex dividend | 11 days |
Days until Dividend pay date | 32 days |
Does MRK pay a reliable dividends?
See MRK dividend history and benchmarks